Results 301 to 310 of about 209,193 (336)
Some of the next articles are maybe not open access.
Tumor angiogenesis inhibitors.
Biochemistry. Biokhimiia, 2003Formation of the blood supply system is a critical step in malignant transformation of neoplasms which results in the penetration of tumor cells into neighboring tissues and metastatic growth. Significant progress in the elucidation of mechanisms underlying tumor angiogenesis and the discovery of a great diversity of biomolecules involved in its ...
Severin Se +3 more
openaire +2 more sources
A diaminoantraquinone inhibitor of angiogenesis.
The Journal of Pharmacology and Experimental Therapeutics, 1994Tumor growth is dependent upon angiogenesis. There is an intense search for pharmacological inhibitors of angiogenesis as a novel approach to treat angiogenic diseases, e.g., arthritis, diabetic retinopathy or cancer. A series of compounds, originally studied as potential protein kinase C inhibitors, included the diaminoanthraquinone NSC 639366 (1-[[3-(
S, Takano +3 more
openaire +2 more sources
Cytokine and Angiogenesis Inhibitors
2005Renal cell carcinoma is an important malignancy accounting for approximately 3% of all adult cancers [1]. The incidence of renal cell carcinoma has been steadily and significantly increasing over the past two decades, with worldwide mortality expected to exceed 100,000 [2].
Timothy G. Eisen +2 more
openaire +2 more sources
Angiogenesis inhibitors and their delivery systems
Applied Biochemistry and Biotechnology, 1983The extensive vascularity of solid tumors has been recognized for over 100 yr (1). However, only in the past 15 yr has the importance of this phenomenon been appreciated and only in the past 6 yr has the possibility of chemical interference been apparent. In this article, we review the emerging field of tumor vascularization inhibitors.
Robert Langer +3 more
openaire +3 more sources
Angiogenesis inhibitors in human endometrium
2022This thesis was scanned from the print manuscript for digital preservation and is copyright the author. Researchers can access this thesis by asking their local university, institution or public library to make a request on their behalf. Monash staff and postgraduate students can use the link in the References field.
openaire +1 more source
Angiozyme: A Novel angiogenesis inhibitor
Current Oncology Reports, 2001Several inhibitors of angiogenesis are being developed for the treatment of cancer. One dominant strategy involves disruption of the vascular endothelial growth factor (VEGF) pathway by inhibition of the receptors for VEGF. Inhibition of the VEGF receptor activity can be accomplished using catalytic RNA molecules known as ribozymes, which downregulate ...
David E. Weng, Nassim Usman
openaire +3 more sources
Novel benzoxazines as inhibitors of angiogenesis
Investigational New Drugs, 2014Dysregulation of angiogenesis has been associated with many pathological disorders, including cancer; where angiogenesis has been found to be critical for the maintenance and metastasis of tumours. One of the pathways involved in the regulation of angiogenesis is the phosphatidylinositol3-kinase (PI3K) signalling pathway.
Sara Al-Rawi +3 more
openaire +3 more sources
Angiogenesis and angiogenesis inhibitors in cancer.
Forum (Genoa, Italy), 1999Angiogenesis, the development of a new blood supply, is an essential process of tumour growth and metastasis. Over the past few years, this has led to the consideration of the tumour vasculature as an optimal target for anti-cancer strategies. The process of angiogenesis consists of a series of interactive events: quiescent endothelial cells are ...
R, Giavazzi, G, Taraboletti
openaire +1 more source
Investigational Angiogenesis Inhibitors
2010Targeting angiogenesis is an evolving field of cancer research. Tumor angiogenesis is considered as an important step in the progression and metastasis of prostate cancer. Several pathways that converge toward promotion of growth, proliferation, and survival of prostate cancer cells have been targeted, including modulation of proangiogenic factors such
William Dahut, Jeanny B. Aragon-Ching
openaire +2 more sources
Resistance to Inhibitors of Angiogenesis
2018Angiogenesis, a process that is predominantly driven by the vascular endothelial growth factor (VEGF) signaling pathway, plays an essential role in tumor progression and metastasis. Accordingly, a range of anti-angiogenic agents, most of which block VEGF or its receptor, have been approved for the treatment of various malignant diseases.
Ksenia Magidey, Yuval Shaked, Nili Dahan
openaire +2 more sources